Citi Lowers Cytokinetics (CYTK) PT to $77 Due to Uneventful Q2 2025 Earnings

Cytokinetics Incorporated (NASDAQ:CYTK) is one of the best upside stocks to invest in now. On August 8, Citi lowered the firm’s price target on Cytokinetics to $77 from $80, while keeping a Buy rating on the shares. This sentiment followed the company’s Q2 2025 earnings report, which the firm views as uneventful.

In Q2, Cytokinetics reported a net loss of $134.4 million, or $1.12 per share, which was an improvement from the net loss of $143.3 million, or $1.31 per share, reported in Q2 2024. Cytokinetics ended the quarter with ~$1.04 billion in cash and investments, which was a decrease from the $1.09 billion reported at the end of Q1 2025.

A lab technician using a microscope to examine the biopharmaceutical company’s molecules.

In terms of clinical development, the FDA extended the PDUFA date for Aficamten to December 26, which may delay the drug’s approval and launch timeline. However, the company noted that all Good Clinical Practice/GCP inspections for Aficamten were completed with no negative observations, which is a positive sign for the regulatory process. The company is preparing for a late-cycle meeting with the FDA in September, which is scheduled to align with the PDUFA date extension.

Cytokinetics Incorporated (NASDAQ:CYTK) is a late-stage biopharmaceutical company that discovers, develops, and commercializes muscle activators and inhibitors as potential treatments for debilitating diseases in the US.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.